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Background: Although the mechanism of neuron loss in Alzheimer’s disease (AD) is enigmatic, it is associated with
cerebral accumulation of Aβ42. The 5XFAD mouse model of amyloid deposition expresses five familial AD (FAD)
mutations that are additive in driving Aβ42 overproduction. 5XFAD mice exhibit intraneuronal Aβ42 accumulation at
1.5 months, amyloid deposition at 2 months, and memory deficits by 4 months of age.
Results: Here, we demonstrate by unbiased stereology that statistically significant neuron loss occurs by 9 months
of age in 5XFAD mice. We validated two Aβ42-selective antibodies by immunostaining 5XFAD; BACE1−/− bigenic
brain sections and then used these antibodies to show that intraneuronal Aβ42 and amyloid deposition develop in
the same regions where neuron loss is observed in 5XFAD brain. In 5XFAD neuronal soma, intraneuronal Aβ42
accumulates in puncta that co-label for Transferrin receptor and LAMP-1, indicating endosomal and lysosomal
localization, respectively. In addition, in young 5XFAD brains, we observed activated Caspase-3 in the soma and
proximal dendrites of intraneuronal Aβ42-labeled neurons. In older 5XFAD brains, we found activated
Caspase-3-positive punctate accumulations that co-localize with the neuronal marker class III β-tubulin, suggesting
neuron loss by apoptosis.
Conclusions: Together, our results indicate a temporal sequence of intraneuronal Aβ42 accumulation, Caspase-3
activation, and neuron loss that implies a potential apoptotic mechanism of neuron death in the 5XFAD mouse.
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The histopathology of Alzheimer’s disease (AD) is char-
acterized by two hallmark lesions, extracellular amyloid-
β plaques made of the Aβ peptide, and intracellular
neurofibrillary tangles composed of hyperphosphorylated
tau (reviewed in [1-5]). In addition to the presence of
plaques and tangles in the brain, considerable neuron
loss is also a cardinal feature of AD, but the mechanisms
of neural cell death are unclear. Importantly, familial AD
mutations (FAD) in the genes for amyloid precursor pro-
tein (APP), presenilin 1 (PS1), and presenilin 2 (PS2)
that cause AD implicate Aβ as an initiating factor in AD
pathogenesis (reviewed in [5,6]). These FAD mutations
increase the production of Aβ42, the 42-amino acid form* Correspondence: r-vassar@northwestern.edu
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distribution, and reproduction in any mediumof the peptide, from APP, which is sequentially cleaved
by the β- and γ-secretase enzymes to release the peptide.
These results, among others, strongly suggest that Aβ42
plays a central early role in the pathophysiology of AD
that ultimately leads to the neuron loss and dementia
observed in the disorder.
The mechanism by which Aβ42 exerts neurotoxicity is
poorly understood; many mechanisms have been
hypothesized, but none have been definitively proven.
The accumulation of intraneuronal Aβ42 has been
observed in the brains of AD patients and APP trans-
genic mice, and studies suggest that intraneuronal Aβ42
plays a role in neurodegenerative processes relevant to
AD (reviewed in [7-9]). Frank neuron loss has been
observed in two aggressive amyloid plaque transgenic
mouse models that also exhibit accumulation of intra-
neuronal Aβ42 prior to plaque formation: the 5XFAD
and APPSLPS1K1 lines [10,11]. These transgenic modelsntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Aβ42 production. In the case of the 5XFAD model, the
mouse overexpresses APP with K670N/M671L (Swedish
mutation [12]), I716V (Florida mutation [13]), and
V717I (London mutation [14]), and PS1 with M146L
and L286V mutations [15]. Individually, each FAD muta-
tion enhances Aβ42 generation, but together they act
synergistically in the transgenic mouse to predominantly
make Aβ42. Consequently, 5XFAD mice represent a very
aggressive amyloid deposition model that develops intra-
neuronal Aβ42 at 1.5 months, plaques at 2 months,
memory deficits at 4 months, and neuron loss at
9 months of age [10]. These characteristics make 5XFAD
mice a robust model for investigating the role of intra-
neuronal Aβ42 in neuron loss.
Here, we have examined the process of neuronal death
in 5XFAD mice and found a correlation between intra-
neuronal Aβ42, neuron loss, and Caspase 3 activation in
large pyramidal neurons of the brain. These results sug-
gest a potential role for an apoptotic mechanism in
intraneuronal Aβ42-mediated neuron loss, and may have
relevance for neuronal death in AD.Figure 1 5XFAD mice exhibit neuron loss in Layer 5 cortex and subic
old non-transgenic littermate (A-E, K-N) and 5XFAD (F-J, O-R) female mice
cortex (A-J) and subiculum (K-R). Numbers indicate cortical layers and das
areas of increased magnification shown in E and J, respectively. The 5XFAD
age as evident by a decrease in stained neurons (H, Q, I, R, J). Increased m
5 of the 5XFAD mouse at 12 months compared to the non-transgenic (E).Results
5XFAD mice exhibit progressive neuron loss in cortical
Layer 5 and subiculum
The 5XFAD transgenic mouse is one of the few amyloid
animal models that exhibits significant neuron loss. Our
previous work demonstrated a qualitative reduction of
5XFAD pyramidal neurons in cortical Layer 5 and subi-
culum at 9 months of age [10]. Moreover, Jawhar and
colleagues have shown a significant quantitative decrease
of 5XFAD Layer 5 neurons at 12 months of age [10,16].
To extend these findings and determine in greater detail
the degree to which 5XFAD mice mirror the progressive
neuron loss observed in human AD, we counted neu-
rons from female 5XFAD mice at ages 4, 6, 9, and
12 months by design-based unbiased stereology. Para-
sagittal 5XFAD and non-transgenic littermate control
brain sections were stained with cresyl violet to visualize
neuronal soma (Figure 1). At 4 and 6 months of age, no
neuron loss in 5XFAD brain was apparent. However, by
9 months of age 5XFAD mice exhibited visible loss of
large pyramidal neurons in cortical Layer 5 (Figure 1H)
and subiculum (Figure 1Q), as previously reported [1].ulum. Parasagittal brain sections from representative 4- to 12-month-
were stained with cresyl violet and micrographed to image Layer 5
hed lines identify borders between layers. Boxes in D and I outline the
mouse exhibits visible loss of large pyramidal neurons at 9 months of
agnification (J) shows a clear loss of large pyramidal neurons in Layer
Scale bar in R = 280 μm for A-D, F-I; 110 μm for E, J; 80 μm for K-R.
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vious neuron loss at any age. These results not only cor-
roborate the 5XFAD neuron loss seen previously [10,16],
but also support the notion of a progressive death of
neurons that is absent at early ages.
Next, we performed unbiased stereology to quantify the
qualitative 5XFAD neuron loss that we observed. Quanti-
tative analysis of large pyramidal neurons in Layer 5 of the
cortex revealed a significant decrease in the number of
neurons from 5XFAD mice at 9 and 12 months when
compared to age matched non-transgenic littermate con-
trol mice (Figure 2A). At 6 months we observed a trend
toward a decrease in neuron number within the 5XFAD
group. Closer examination revealed two different 5XFAD
mouse sub-groups: a normal group and another subset of
mice that had succumbed to neuron loss (Figure 2B). The
onset of neuron loss around 6 months of age appeared to
be somewhat variable, but suggested that neuronal death
may start in the 6 month old 5XFAD cohort. Neuron
numbers of 5XFAD mice at younger ages and of all non-
transgenic mice were not significantly different from each
other. These results suggest a progressive death of neu-
rons in 5XFAD mice that begins to become a major
process around the age of 6 months and culminates in a
~25% loss of Layer 5 pyramidal neurons by 12 months of
age.Figure 2 Unbiased stereological analysis of 5XFAD mice reveals
significant neuron loss in cortical Layer 5 at 9 and 12 months
of age. Brains from age-matched non-transgenic littermate (non-Tg)
and 5XFAD female mice were sectioned at 30 μm and stained with
cresyl violet and imaged by light microscopy. Large pyramidal
neurons were then counted in Layer 5 cortex using an optical
fractionator. (A) Large pyramidal neuron numbers in non-transgenic
and 5XFAD Layer 5 cortex from mice aged 4–12 months. At 9 and
12 months there is a statistically significant decrease in the number
of large pyramidal neurons in 5XFAD compared to non-transgenic
mice (* p<0.05, ** p<0.01; n = 5 mice per group). 5XFAD mice
exhibited a progressive decrease in Layer 5 large pyramidal neuron
number, which at 12 months represented a 24.8% loss compared to
non-transgenic mice. (B) 6 month 5XFAD mice are separable into
two subgroups: those with normal neuron counts (6Mo 5XFAD
high) and those with low neuron counts indicating neuron loss
(6Mo 5XFAD low). The 5XFAD low count group showed a
statistically significant decrease in neuron number compared to age
matched non-transgenic and 5XFAD normal count groups (* p<0.05,
** p<0.01, n = 5 non-Tg, n = 10 net 6 month 5XFAD).Together, our results confirm and extend our previous
qualitative work [10] and the quantitative study of
Jawhar and colleagues [16] demonstrating neuron loss in
the 5XFAD model. In addition, our data indicate that
5XFAD neuron loss occurs at earlier ages than previ-
ously shown and appears to begin when mice are about
6 months old. Thus, the 5XFAD model should prove
useful for studies of Aβ-associated neurodegeneration
and neuron loss.
5XFAD mice exhibit intraneuronal Aβ42 accumulation that
precedes amyloid plaque formation
We anticipated that the 5XFAD neuron loss in cortical
Layer 5 and subiculum would correspond to an elevated
amyloid plaque load in these areas, as we previously
observed [10]. To investigate this further, we performed
immunohistochemistry using a rabbit monoclonal antibody
that selectively recognizes the carboxy (C)-terminal neo-
epitope of Aβ42 generated after γ-secretase cleavage; this
antibody has minimal cross-reactivity with full-length APP
and APP C-terminal fragments (CTFs; Figure 3 and 4). As
expected, parasagittal 5XFAD brain sections incubated
with the Aβ42 selective antibody displayed a progressive
increase in amyloid burden with age (Figure 3A-D). At
4 months, 5XFAD mice exhibited moderate Aβ42 plaque
deposition that was more dense in cortical Layer 5 and
subiculum (Figure 3A). As 5XFAD mice aged through 6, 9,
and 12 months, the number of Aβ42 plaques increased,
and deposits began to accumulate in brain regions adjacent
to Layer 5 and subiculum, such as CA1/2, CA3, dentate
gyrus, Layers 4 and 6 of the cortex, and midbrain
(Figure 3B-D). As expected, non-transgenic littermate con-
trol mice exhibited no Aβ42–positive deposits at any age
(12 months, Figure 3F). As an additional negative con-
trol, we immunostained sections from a 9 month-old
5XFAD; BACE1−/− mouse and observed no Aβ42 label-
ing (Figure 3E). Importantly, the lack of Aβ42 signal in
5XFAD; BACE1−/− brain sections validated the selectiv-
ity of our anti-Aβ42 antibody, confirming that the
antibody did not cross-react with full length APP or
APP C-terminal fragments, and verified that plaque
deposition requires BACE1 activity, as previously shown
[17-20]. Together, these observations demonstrate that
the regions with the greatest age-related Aβ42 depos-
ition are also the same regions that exhibit neuron loss
in 5XFAD brain.
5XFAD mice develop intraneuronal Aβ42 at an early age
Previous studies have suggested that intraneuronal Aβ is
a potentially important factor participating in AD patho-
genesis (reviewed in [8,21,22]). Our initial work demon-
strated the presence of intraneuronal Aβ42 in 5XFAD
mice starting at ~1.5 months [10], an observation that
has been recently confirmed independently by several
Figure 3 5XFAD mice exhibit intraneuronal Aβ42 prior to amyloid deposition and neuron loss. Parasagittal brain sections from 1.5 (G), 2
(H), 4 (A, I-T), 6 (B), 9 (C, E), and 12 (D, F) month mice were incubated with anti-Aβ42 C-terminal neo-epitope antibody, visualized by DAB
staining, and micrographed. 5XFAD mice display progressive Aβ42-positive plaque deposition with age (A-D). In 5XFAD Layer 5 cortex,
intraneuronal Aβ42 (arrows) is first observed at 1.5 months (G) and amyloid plaques at 2 months (H) of age. At high magnification, intraneuronal
Aβ42 staining is confined within numerous small spherical puncta dispersed throughout the cytoplasm of the soma of large pyramidal neurons
(K-O). The appearance of these Aβ42-positive puncta suggests membrane-bound intracellular compartments such as endosomes or lysosomes.
Importantly, the absence of Aβ42 staining in 5XFAD; BACE1−/− neurons (E, P-T) demonstrates the selectivity of the antibody for Aβ42, and
indicates that the antibody dos not cross-react with endogenous or transgenic APP under the conditions used. Aβ42 staining is also lacking in
non-transgenic littermate (Non-Tg) sections (F, J). Scale bar = 400 μm (A-F), 40 μm (G-J), 9 μm (K-T).
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5XFAD mice, we immunostained brain sections from 1.5,
2, and 4 month old mice with anti-Aβ42 selective antibody
(Figure 3G-J). At 1.5 months, before the appearance of
amyloid plaques, many large pyramidal neurons in cortical
Layer 5 displayed numerous strongly stained Aβ42-positive
puncta within their soma (Figure 3G). Intraneuronal Aβ42
staining was present when amyloid deposition began at
~2 months and persisted as plaque number increased with
age (Figure 3H,I arrows). However, intraneuronal Aβ42 be-
came more difficult to visualize over time, suggesting that
either intraneuronal Aβ42 accumulation is transient [27],
or intracellular Aβ42 signal is obscured as plaque staining
intensifies with age. Non-transgenic littermate controlsections lacked both plaques as well as intraneuronal
Aβ42-positive puncta (Figure 3J), as expected.
The presence of intraneuronal Aβ in AD and APP
transgenic brains has been controversial. One criticism
against intraneuronal Aβ has been that anti-Aβ anti-
bodies also recognize full-length APP and APP-CTFs,
depending on the antibody (e.g., see [28]). To ensure
that our selective anti-Aβ42 antibody was detecting bona
fide intraneuronal Aβ42 and was not cross-reacting with
APP or APP CTFs, we performed antibody titration
experiments on both 5XFAD; BACE1+/+ and 5XFAD;
BACE1−/− brain sections. At a primary antibody dilution
of 1:20,000, punctate Aβ42-positive staining was detected
in the soma of large pyramidal neurons in cortical Layer
Figure 4 Intraneuronal Aβ42 is partially localized within both endosomes and lysosomes in 5XFAD neurons. Parasagittal brain sections of
5XFAD (A, B, E-K) and 5XFAD; BACE1−/− (C, D) brains were co-stained with anti-Aβ42-selective antibody (A-K) and anti-APP (6E10: B, D; Karen [29]:
E) or anti-Transferrin receptor (TfR) (F-H) or anti-LAMP1 (I-K) antibody, and DAPI for nuclei (A-K), and imaged by confocal microscopy. All mice
were 4 months old, except mice used for LAMP1 immunostaining were 2 months (I-K). Label colors indicate fluorescence color. Note that APP
staining appears widely distributed in the soma and cell surface (B, D, E), while Aβ42 labeling is confined to intraneuronal puncta in 5XFAD mice
(A, B, E, F, I). Asterisk in E identifies Aβ42-positive plaque (red) above large pyramidal neuron that exhibits intraneuronal Aβ42 puncta (arrow).
lntraneuronal Aβ42 signal is absent in 5XFAD; BACE1−/− neurons (C, D), again demonstrating the Aβ42-selectivity of the antibody. In 5XFAD
neurons, intraneuronal Aβ42 co-localizes with Transferrin receptor in early endosomes (F-H) and with LAMP1 in late endosomes and early
lysosomes (I-K), at least in part. Scale bar in D = 12μm (A, C); = 20 μm (B, D). Scale bar in K = 12 μm (E); = 20 μm (F-K).
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signal was observed in 5XFAD; BACE1−/− sections
(Figure 3P-T). Because 5XFAD; BACE1−/− mice express
the APP transgene but do not generate Aβ [18], these
results strongly support the conclusion that our anti-
Aβ42-selective antibody does indeed detect intraneuro-
nal Aβ42 rather than full-length APP or APP CTFs.
To further confirm that our anti-Aβ42-selective anti-
body does not cross-react with APP, we performed
confocal immunofluorescence microscopy on 5XFAD;
BACE1+/+ and 5XFAD; BACE1−/− brain sections co-
stained with anti-Aβ42-selective and APP antibodies.
5XFAD sections showed punctate labeling of Aβ42
throughout the neuron soma (Figure 4A,B,E,F,I), while
anti-human APP (6E10) staining revealed additional
punctate and cell-surface labeling that were negative for
Aβ42 (Figure 4B). As expected, Aβ42 signal wascompletely absent in the 5XFAD; BACE1−/− sections
(Figure 4C,D), but transgenic APP labeling was evident
(Figure 4D), again demonstrating that our Aβ42-selective
antibody does not recognize full-length APP or APP
CTFs at the concentration used. Co-staining 5XFAD
brain sections with anti-Aβ42 and a second anti-APP anti-
body (Karen, [29]) produced similar results (Figure 4E).
Together, our data demonstrate that the anti-Aβ42 C-
Terminal neo-epitope antibody does not have significant
cross-reactivity with APP, and that punctate Aβ42 immu-
noreactivity resides within 5XFAD neuronal soma.
Intraneuronal Aβ42 co-localizes with endosomal and
lysosomal markers
The punctate Aβ42 immunolabeling in neuronal soma
suggested that Aβ42 might be contained within
membrane-bound subcellular compartments. Previous
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somes and late endosomal multivesicular bodies in other
models [30-32] and in cathepsin-D-positive puncta of
5XFAD mice [25]. To further investigate the subcellular
localization of Aβ42 in 5XFAD neurons, brain sections were
co-immunostained with anti-Aβ42 and anti-Transferrin
receptor or anti-LAMP1 antibodies to identify endosomes
or lysosomes, respectively, and imaged by immunofluor-
escence confocal microscopy. Indeed, we observed
partial co-localization of punctate Aβ42 staining with
signals from both Transferrin receptor and LAMP1
(Figure 4F-K). Although Aβ42 co-localization was
observed with both markers, neither was exclusive.
These results suggest the accumulation of intraneuronal
Aβ42 throughout the endosomal-lysosomal system.Figure 5 5XFAD mice exhibit Caspase-3 activation in Layer 5 cortex a
9 month old 5XFAD (A-D, I-L), non-transgenic littermate (Non-Tg; E, F, M,
antibody against activated Caspase-3, visualized by DAB staining, and micro
activated Caspase-3 immunolabeling are significantly higher in the brains o
non-transgenic mice. In addition, punctate aggregates of activated Caspase
but are absent in 5XFAD; BACE1−/− or Non-Tg sections (E-H, M-P). Boxes in
B, E-H, I, J, M-P = 80 μm; C, D, K, L = 40 μm.5XFAD brains exhibit increased Caspase-3 activation
The pathogenic mechanisms leading to neuron loss in
AD are not well understood. Studies in cultured human
neurons have shown an association of intraneuronal
Aβ42 with increased levels or activation of BAX and p53,
suggesting that apoptosis may play a role in AD-related
neuron loss [33]. To determine whether apoptosis might
be involved in the loss of 5XFAD neurons, parasagittal
brain sections were incubated with an antibody against
the neo-epitope generated following activation of Cas-
pase-3, a strong indicator of apoptosis. Overall, 5XFAD
sections of Layer 5 cortex and subiculum displayed
higher activated Caspase 3 immunostaining intensity
than non-transgenic littermate and 5XFAD; BACE1−/−
sections (Figure 5A-D, I-L vs. 5E-H M-P). Closend subiculum. Parasagittal brain sections from representative 4 and
N), and 5XFAD; BACE1−/− (G, H, O, P) mice were incubated with an
graphed in Layer 5 cortex (A-H) and subiculum (I-P). The levels of
f both ages of 5XFAD mice compared to those of 5XFAD; BACE1−/− or
-3 are distributed throughout 5XFAD sections (black arrows, A-D, I-L),
A, B, I, and J are enlarged in C, D, K, and L, respectively. Scale bar A,
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5XFAD mice revealed the presence of punctate aggrega-
tions of activated Caspase-3 (Figure 5A-D, I-L, arrows).
These activated Caspase-3-positive puncta were smaller
than neuron soma, typically ~2-8 μm in diameter, and
were located almost exclusively in Layer 5 cortex and
subiculum, the sites of localization of intraneuronal Aβ42
and 5XFAD neuron loss (Figure 5C,D,K,L, arrows). No
Caspase-3-positive puncta were observed in non-
transgenic littermate or 5XFAD; BACE1−/− sections
(Figure 5E-H, M-P). The presence of activated Caspse-3-
positive accumulations was confirmed in 5XFAD Layer 5
cortex and subiculum at the ages of 6 and 12 months
(data not shown), in addition to 4 and 9 months. Immu-
noblot analysis failed to detect the presence of activated
Caspase-3 in 5XFAD whole-brain homogenates (not
shown), however this was likely the result of dilution ofFigure 6 5XFAD mice have elevated levels of activated Caspase-3 in n
from 1.5, 4, and 9 month old 5XFAD mice were co-incubated with antibod
tubulin (red; A-F) or NeuN (red; G-L) and imaged by confocal microscopy.
immunolabeling with neuronal markers β-tubulin and NeuN demonstrate C
Caspase-3 labeling in proximal dendrites of large pyramidal neurons of Lay
number of Caspase-3-positive proximal dendrites is reduced in 9 month ol
are more prevalent at older ages suggesting a progressive process (spheric
aggregates become apparent at 4 months in Layer 5 cortex and later in su
point to Caspase-3-positive aggregates that co-label with neuron-specific cthe activated Caspase-3 signal below the level of detection.
Overall, our results suggest that apoptotic processes are
present in 5XFAD mice beginning at 4 months, before the
start of neuronal death at 6 months, in the same brain
regions that exhibit intraneuronal Aβ42, amyloid plaques,
and neuron loss.
The localization of activated Caspase-3 to regions of
both Aβ42 accumulation and neuron loss implied poten-
tial causal links between these factors. To initially inves-
tigate this possibility, we first needed to confirm that
activated Caspase-3 was indeed associated with neurons.
Therefore, we co-incubated brain sections from 1.5, 4,
and 9 month old 5XFAD mice with antibodies against
the neuronal markers class III β-tubulin (TUJ1) or NeuN
(A60) and activated Caspase-3, and performed immuno-
fluorescence confocal microscopy. By 1.5 months, acti-
vated Caspase-3 immunostaining was identified in theeurons of Layer 5 cortex and subiculum. Parasagittal brain sections
ies against activated Caspase-3 (green) and neuron-specific class III β-
Sections were co-stained with DAPI to detect nuclei (blue). Co-
aspase-3 activation in 5XFAD neurons. Note the presence of activated
er 5 cortex and subiculum at 1.5 and 4 months (A-D, G-J), The
d compared to younger 5XFAD mice, although Caspase-3 aggregates
al green structures in E, F, K, L). Activated Caspase-3-positive
biculum, and likely represent neuronal apoptotic bodies. Arrows in F
lass III β-tubulin. Scale bar = 20 μm.
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positive large pyramidal neurons in both Layer 5 cortex
and subiculum (Figure 6A-D, G-J). At this age, activated
Caspase-3 had not yet aggregated into puncta. However,
by 4 months of age, spheroid accumulations of activated
Caspase-3 had become apparent in Layer 5 cortex and
subiculum (Figure 6C,D). In some cases, activated
Caspase-3-positive puncta co-localized with β-tubulin
in structures that were reminiscent of degenerating
neurons (Figure 6F, arrows). Activated Caspase-3 co-
localization with NeuN was less prominent, presumably
because neuronal nuclei, the predominant site of
NeuN subcellular localization, were largely degener-
ated (Figure 6K). These results confirmed the presence
of activated Caspase-3 in 5XFAD neurons that were
likely in the process of degeneration via apoptosis.
At this point, we had established the presence of acti-
vated Caspase-3 in large pyramidal neurons in Layer 5
cortex and subiculum of 5XFAD mice, but we had not
demonstrated a direct association between activated
Caspase-3 and intraneuronal Aβ42. Toward this end, we
immunostained brain sections of 1.5 and 4 month old
5XFAD, non-transgenic littermate, and 5XFAD; BACE1−/−
mice with anti-activated Caspase-3 and anti-Aβ42-selective
antibodies and imaged sections by confocal microscopy
(Figure 7). Non-transgenic and 5XFAD; BACE1−/− brain
sections showed no specific immunostaining for Aβ42 or
activated Caspase-3 (Figure 7E-J), confirming both theFigure 7 5XFAD mice display Caspase-3 activation in neurons with in
and 4 month (B, D, F, H-J, L) 5XFAD (A-D, K, L), non-transgenic littermate
with antibodies against activated Caspase-3 (green) and Aβ42 C-terminal ne
co-stained with DAPI to detect nuclei (blue). Activated Caspase-3 is presen
subiculum (C, D) that also display intraneuronal Aβ42. At high magnificatio
proximal dendrites of Aβ42-positive neurons (K, L). Neither activated Caspa
5XFAD; BACE1−/− (I, J) mice. Note presence of amyloid plaques (red) at 4 m
structures (arrows, B, D) may represent neurons in the process of degenera
J = 20 μm; K, L = 10 μm.selectivity of the anti-Aβ42 antibody and the dependence
of Caspase-3 activation on BACE1 cleavage of APP. In
contrast, Layer 5 cortex and subiculum from 1.5 and
4 month old 5XFAD mice revealed both activated
Caspase-3 and Aβ42 immunostaining (Figure 7A-D,K,L).
Importantly, 5XFAD large pyramidal neurons that dis-
played activated Caspase-3 immunostaining in proximal
dendrites, presumably representing an early stage of apop-
tosis, exhibited punctate intraneuronal Aβ42 labeling in
soma (Figure 7K,L). 5XFAD neurons devoid of intraneur-
onal Aβ42 staining also lacked evidence of Caspase-3 acti-
vation. Interestingly, at 4 months of age, 5XFAD sections
not only exhibited activated Caspse-3 positive aggregates
in both the Layer 5 cortex and subiculum, but these pro-
files were consistently in close proximity to Aβ42-positive
plaques (Figure 7B,D, arrows). Taken together, our results
suggest apoptosis, via activation of Caspase-3, as a primary
mechanism of neuron loss resulting from intraneuronal
Aβ42.
Discussion
Despite years of study, the mechanisms of neuron loss in
AD are still incompletely understood. Apoptosis has
been proposed as a potential mechanism leading to the
neuronal death observed in this devastating neurodegen-
erative disorder (reviewed in [34-36]). Here, in the
5XFAD amyloid plaque mouse model, we have demon-
strated progressive loss of neurons that correlatestraneuronal Aβ42. Parasagittal brain sections from 1.5 (A, E, C, G, K)
(Non-Tg; E-H), and 5XFAD; BACE1−/− (I, J) mice were co-incubated
o-epitope (red) and imaged by confocal microscopy. Sections were
t in 5XFAD large pyramidal neurons of Layer 5 cortex (A, B, K, L) and
n, activated Caspase-3 is distributed throughout in the soma and
se-3 nor intraneuronal Aβ42 are present in neurons of Non-Tg (E-H) or
onths in 5XFAD brain (B, D). Activated Caspase-3-positive ring-like
tion. Asterisk in A identifies background capillary staining. Scale bar A-
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tivation. We observe a time course in 5XFAD mice in
which intraneuronal Aβ42 first appears at 1.5 months of
age in large pyramidal neurons of Layer 5 cortex and
subiculum, concomitant with the observation of acti-
vated Caspase-3 in these neurons, but prior to amyloid
deposition. By 4 months of age, 5XFAD mice exhibit
amyloid plaques and the appearance of Caspase-3 posi-
tive puncta in Layer 5 cortex and subiculum that suggest
neurodegeneration, but at a time when statistically sig-
nificant neuron loss is not yet evident. At 6 months of
age, 5XFAD mice as a whole show a trend toward
neuron loss, in which Layer 5 neurons appear to split
into two subgroups, those that display neuron loss and
those that do not. However, by 9 months, neuron loss is
statistically significant in Layer 5 cortex of 5XFAD mice.
This time course, although correlative, suggests the possi-
bility that intraneuronal Aβ42 triggers Caspase-3 activation,
which in turn induces apoptosis-mediated neurodegenera-
tion and eventual neuron loss in 5XFAD mice.
The 5XFAD mouse, along with the APPSLPS1KI, is
one of a few known mouse models that exhibits signifi-
cant neuron loss in addition to displaying other AD hall-
marks such as amyloid plaques [10,11,16]. Our unbiased
stereological counting of 5XFAD mice revealed a signifi-
cant decline in large pyramidal neurons of the Layer 5
cortex starting at 9 months of age. Our data is consistent
with previous studies, except we have demonstrated that
significant 5XFAD neuron loss begins at an earlier age
than previously reported [16]. Interestingly, a division
develops at 6 months that appears to separate 5XFAD
mice into those that exhibit significant neuron loss and
those that have yet to surpass the point where neuron
loss is occurring at a measurable rate. The ~6 month
age period marks the first appearance of oligomeric N-
terminally truncated Aβ peptides with pyroglutamate
and an increasing decline of motor abilities in 5XFAD
mice [16,23].
Consistent with previous studies [10,32], we observed
intraneuronal Aβ42 as small puncta located in neuronal
soma of 5XFAD mice. The intraneuronal Aβ42 became
progressively more difficult to detect in 5XFAD sections
after 1.5 months of age, presumably because highly con-
centrated Aβ42 plaques effectively blocked visualization
of smaller and less prominent intraneuronal Aβ42
puncta. Despite this difficulty, 5XFAD mice exhibited a
subset of neurons that harbored intraneuronal Aβ42 past
4 months. The early appearance of intraneuronal Aβ42
and its correlation with neuron loss in 5XFAD mice is
also shared with the APPSLPS1KI transgenic mouse
model [11,33,37,38].
We found that intraneuronal Aβ42 in 5XFAD mice
was partially co-localized to endosomes and lysosomes,
as indicated by co-labeling for Transferrin receptor andLAMP1, respectively. This corresponded well with previ-
ous findings that intraneuronal Aβ42 localizes to late
endosomal multivesicular bodies [32] or lysosomes [25];
the latter observation is particularly significant, as it was
obtained in the 5XFAD mouse. Intraneuronal Aβ42
localization to endosomes and lysosomes is also sup-
ported by previous studies that have proposed a mech-
anism in which the ubiquitin-proteasome system is
disrupted, causing impaired protein degradation and
increased Aβ accumulation [39,40].
It has been hypothesized that apoptosis is involved in
the neuron loss seen in AD (reviewed in [34-36]). For
example, activated Caspase-3 immunoreactivity has been
reported to be present in AD brain [41,42] and in APP
transgenic mice [43,44]. Interestingly, Aβ42 has been
shown to cause cytochrome c release from mitochondria
[45], which activates Caspase-3 and induces apoptosis,
thus providing a potential mechanism for intraneuronal
Aβ42-mediated neuron loss in 5XFAD mice.
In 5XFAD mice, activated Caspase-3-positive puncta
were present throughout Layer 5 cortex and subiculum,
often in close proximity to Aβ42-positive plaques.
Caspase-3 activation was not apparent in both aged
matched non-transgenic littermate and 5XFAD; BACE1−/−
mice. We speculate that these activated Caspase-3-
positive puncta are likely the remnants of neurons that
died by apoptosis, a conclusion supported by the observa-
tion of co-localized activated Caspase-3 and neuron-
specific class III β-tubulin (Figure 6F). The Caspase-3
puncta in 5XFAD brain are reminiscent of activated
Caspase-3-positive AD neurons that exhibit typical fea-
tures of apoptosis such as condensed cytoplasm and
shrunken nuclei [46,47]. In addition, the association of
activated Caspase-3 and neuron loss in 5XFAD mice is
consistent with the findings of apoptotic neuron death
and “apoptotic bodies” found in a different PS/APP
(PS1M146L and K670N/M671L) mouse model of AD
[48]. While not always coexistent, we observed large pyr-
amidal neurons from 1.5 month-old 5XFAD mice that
contained both punctate intraneuronal Aβ42 within the
neuron soma and activated Caspase-3 throughout the cell
body and proximal dendrites (Figure 7K, L). We speculate
that these neurons could represent an early stage of
apoptotic neuronal degeneration and death. Interestingly,
a recent study found activated caspase-3 in dendritic
spines of hippocampal neurons in the Tg2576 APPswe
transgenic mouse model [49], supporting the dendritic
localization of activated Caspase-3 that we have observed
in 5XFAD mice.
Conclusions
The 5XFAD mouse has proven to be a useful model of
amyloid deposition in the brain. Here, we have extended
the utility of this transgenic mouse to the investigation
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compelling correlative data that associates intraneuronal
Aβ42 with Caspase-3 activation and neuron death. Our
data suggest a mechanism whereby intraneuronal Aβ42 ac-
cumulation in the endosomal-lysosomal pathway leads to
activation of Caspase-3 and apoptotic neuron death in
5XFAD mice. Although some caution is warranted in
interpreting results from an aggressive amyloid mouse
model that overexpresses multiple FAD mutations, our
results are consistent with evidence of activated Caspase-3
and apoptotic neuron death in human AD. Our study pro-
vides a framework that, with further elucidation of
mechanisms, could lead to a deeper understanding of
neuron loss in AD.
Methods
5XFAD transgenic mice
5XFAD mice overexpress the K670N/M671L (Swedish),
I716V (Florida), and V717I (London) mutations in
human APP (695), as well as M146L and L286V muta-
tions in human PS1. The generation of the 5XFAD mice
has been described previously [10].
Tissue collection
Mice were euthanized following IACUC approved pro-
cedures to minimize pain. After dissection, one hemi-
brain of each mouse was fixed in paraformaldehyde/PBS
and cryo-preserved in 30% sucrose/PBS containing
0.01% sodium azide. Brains were sectioned sagittally on
a freezing microtome at 30 μm. Serial sections were col-
lected in 0.1 M phosphate buffer, pH 7.6.
Stereology
Every sixth section was taken in sequential order, thor-
oughly washed in PBS, and then mounted on charged
slides. Sections were allowed to dry between 1.5 to
2.5 hours. Slides were then taken through the cresyl vio-
let staining procedure, where at each step the slides were
slightly agitated every 15 seconds to ensure uniform
staining. The sections were first briefly rinsed in water
and then stained in 0.5% cresyl violet for 10 min. Sec-
tions were then rinsed in water briefly and then dehy-
drated in 50%, 70%, and 90% EtOH solutions for
30 seconds each. Sections were then de-stained in a 95%
EtOH/1.4% glacial acetic acid solution for 1 min. Finally
sections were dehydrated in a series of alcohols, cleared
in xylene, and cover-slipped. The Layer 5 of the cortex
was sampled for each section (1600 μm was examined
starting at the point dorsal to the anterior most part of
CA3 and then moving to the posterior of the brain). A
Nikon (Tokyo, Japan) Eclipse 80i microscope with a
motorized stage, StereoInvestigator 9 (Microbrightfield,
Williston, VT, USA), and a 60x air lens was used to per-
form the stereological counting. Neuronal nuclei werethen randomly sampled from the defined the Layer 5
using optical dissector probes, and a neuronal popula-
tion was determined using a 2 μm top and bottom guard
zone. Comparison of means using the t-test was per-
formed using GraphPad Prism (GraphPad Software, Inc.,
San Diego, CA).
Immunohistochemistry
Free-floating sections were washed in PBS with 0.4%
Triton and then blocked in 3% goat serum for one hour.
Sections were then incubated at 4°C on a shaker over-
night with the following primary antibodies: rabbit
monoclonal anti-Aβ42 (1:1000; Invitrogen; 700254) or
rabbit monoclonal anti-cleaved Caspase-3 (1:1000; Cell
Signaling; 9664). After more washes, the sections were
incubated overnight at 4°C on a shaker with secondary
biotinylated goat anti-rabbit at 1:1000. After a third set
of washes, The Vector Laboratories (Burlingame, CA)
ABC kit was used with 3,30-Diaminobenzidine (DAB) as
chromogen to visualize the reaction product. The sec-
tions were then mounted on charged slides, allowed to
dry, dehydrated in a series of alcohols, cleared in xylene,
and cover-slipped. Light microscopy was performed on a
Nikon (Tokyo, Japan) Eclipse 80i microscope.
Immunofluorescence confocal microscopy
Free-floating sections were treated with TBS with 0.1%
SDS and 5 mM DTT for 30 min on a shaker. Sections
were washed in TBS and then blocked in 5% goat or don-
key serum for one hour (respective to the secondary being
used). Sections were incubated at 4°C on a shaker over-
night with the following primary antibodies: rabbit mono-
clonal anti-Aβ42 (1:1000; Invitrogen; 700254), mouse
monoclonal anti-Aβ42 (1:1000; Covance; SIG-39142),
rabbit monoclonal anti-cleaved Caspse-3 (1:1000; Cell
Signaling; #9664), rat monoclonal anti-Transferrin recep-
tor (1:500; Abcam; ab60344), rat monoclonal anti-LAMP1
(1:500; Abcam; ab25245), 6E10 mouse monoclonal anti-
Aβ (1:1000; Chemicon; MAB1560), Karen goat polyclonal
anti-N-terminal APP (1:500; [29]), DAPI (Invitrogen).
After more washes, the sections were incubated for 1.5 h
at room temperature on a shaker with Invitrogen Alexa
Fluor secondary antibodies at 1:1000 (Donkey anti-Mouse
or Rabbit-488 or 594; Goat anti-Mouse or Rabbit-488 or
594) and DAPI at 300nM. The sections were then
mounted on charged slides and immediately cover-slipped
using ProLong Gold (Invitrogen). Confocal images were
captured on a Nikon (Tokyo, Japan) Eclipse C1si spectral
laser scanning confocal microscope.
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